Studio di Fase III #NATALEE, presentati ad #ESMO26 i risultati dell’analisi di follow-up a 6 anni.

Medinews· @Medinews_ · X·2026-10-23 19:54· 2 天前评分70

正文 · 原文

Ne parliamo qui: https://www.medinews.it/comunicati/ribociclib-dimostra-un-beneficio-in-termini-di-sopravvivenza-globale-nella-piu-ampia-popolazione-di-pazienti-con-tumore-della-mammella-hr-her2%e2%88%92-in-fase-iniziale/

@myESMO

42 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：Medinews · x.com